Search Results

Hyalex Orthopaedics today announced that patients have successfully received HYALEX Knee Implants as part of the company’s first-in-human clinical trials of its novel HYALEX Knee Cartilage System.

Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, announced the appointment of Thomas “Tad” Vail, M.D., as chief medical officer.

Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced that Carl Vause, the company’s president and chief executive officer, will deliver a corporate presentation as part of the Canaccord Genuity 2024 Musculoskeletal Conference.

Hyalex Orthopaedics, Inc., announced that the HYALEX® Cartilage System has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

Hyalex Orthopaedics, a privately-held medical device company developing transformational cartilage biomimetic products, announced the appointment of Carl Vause as its new chief executive officer and president.

Hyalex Orthopaedics launched in May 2017 as a medical device company that intends to advance new products featuring HYALEX technology, a synthetic polymer that mimics cartilage.

Brad Vale, PhD, DVM General Partner at Strategic Healthcare Investment Partners, will join the board as part of the financing

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.